Du är här


Active Biotech: Active Biotech AB Interim report January - March 2014


* On January 24, the laquinimod (Nerventra®) market application received a
negative opinion by the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA).
* Teva has requested a re-examination of the CHMP's opinion.
* In February 2014, Teva decided not to proceed with the randomization stage
of the planned LIBRETTO trial for the treatment of relapsing remitting
multiple sclerosis (RRMS) since the current design is no longer aligned
with the regulatory strategy.
* The ongoing US pivotal clinical study CONCERTO is continuing according to
plan. The results are expected in 2016.


* In February 2014, Ipsen launched a randomized, double-blind,
placebo-controlled Phase III study of tasquinimod in chemo-naive CRPC
patients in Asia.
* The Phase III 10TASQ10 study is proceeding as planned; the primary analysis
of progression-free survival (PFS) and overall survival (OS) is expected in

Paquinimod (57-57)

* In January 2014, paquinimod, for the treatment of systemic sclerosis, was
granted orphan drug status by the US Food and Drug Administration (FDA).
Orphan drug status in the US provides advantages such as market exclusivity
for a period of seven years upon approval.

Financial summary

* Net sales 2.1 (2.4) MSEK
* Operating loss -59.2 (-77.0) MSEK
* Loss for the period -60.2 (-78.0) MSEK
* Loss per share -0.80 (-1.10) SEK

For further information, please contact:

|Tomas Leanderson, Active Biotech AB |
| |
| |
|President and CEO (Corp. Reg. No. 556223-9227) |
| Box 724, SE-220 07 Lund |
| Tel: +46 (0)46 19 20 00 |
|Tel: +46 (0)46 19 20 95 Fax: +46 (0)46 19 11 00 |
| The report is also available at |
| |
| |
|Hans Kolam, CFO www.activebiotech.com |
| |
| |
|Tel: +46 (0)46 19 20 44 |
Active Biotech AB Interim report January - March 2014


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.